A nice little continuation and it is nice to see the XBI above $75 but there is a lot of work to do. To put it in perspective, the 50 day MA is $82.43 and the 200 day MA is $82.22. On the positive, even after the nice little run the RSI is still under […]
March 31st Biotech Update
Yesterday was a disappointment in many ways. To see the sector underperform yet again was frustrating. As frustrating as it was it does not take the move to $78 off the table and it’s good that we are rebounding today. I still think that a move to the $78 area is most likely in the […]
March 30th Biotech Update
We have so far avoiding the worst case scenario by having a nice little rally this week. The next big test is going to be whether or not we can get above $78. That looks like some significant resistance and a place where a lower high can be established that would start to paint a […]
March 29th Biotech Update
I sort of expected a stronger start to the week but perhaps there was more caution than relief buying. We might now be building some momentum assuming investors become less concerned about a pending banking collapse. In other words, rather than the early week strong relief rally, we simply needed a couple days of calm […]
March 27th Biotech Update
Last week ended on a good note that has so far continued. We need a lot more than a couple day bounce to persuade anyone that the tide has changed but it is a start. We re probably starting a rally to the $78 area on the XBI but that really is likely the next […]
March 23rd Biotech Update
Are we heading to $60 on the XBI or not? We sort of broke below the last bit of support yesterday that seemed to clear the way for another 20% or so decline. It could also have been a head fake that then leads to a reversal. I would not look too positively on the […]
March 22 Biotech Update
I believe today is Fed day and my expectation is that there is a 66% chance of a 25 basis point hike and 33% chance of a pause (and 1% of some other action). I think regardless of the action the tone will certainly shift more dovish or at least more cautious given the recent […]
March 21st Biotech Update
The markets are holding in there, which is probably not awful at this point. While most probably expected larger moves, a slow grind at these levels and a steady move higher is probably a healthier sign for the future of the market. Of course, the banking crisis moves fast and events could once again spiral […]
March 20th Biotech Update
An interesting weekend that leads to a basically flat opening? I do not know anyone who would have placed bets on a relatively flat opening given that the global banking crisis seems to have accelerated with CS being bought by UBS. If this was the culmination of the banking crisis, then you would have expected […]
March 17th Biotech Update
Volatility continues as questions around banks both at home and abroad remain. The actions to support a number of banks has also been met with a lukewarm response. There were initially a positive reaction but that has seen tapered off as questions remain both on the individual banks, the banking system, the economy, and the […]
March 16th Biotech Update
The banking crisis continues as CS looks to be the latest bank in the crosshairs. To be fair, there seems to have been questions around CS for years and so it is not necessarily something new but it obviously has become acute. I think it is difficult to see CS going under as one of […]
March 15th Biotech Update
Not the best start to the day. It seems like banks are taking a hit (and not just the regionals but even the too big to fail variety) and as long as the market perceives a banking crisis, it will be difficult for the market to rally. To be fair when you have two of […]
March 14th Biotech Update
Inflation came within expectations (with expectations that it continues to slowly cool although it still remains high). I think the 50 bps hike is completely off the table at this point and I would lean towards a pause over the 25 bps hike. I am not as aggressive in thinking that the Fed pauses but […]
March 13th Biotech Update
Quite the start to the week and it would be quite disappointing if all the news does not get at least a snap back rally in the sector but there are a lot of moving parts. We have both major macro news as well as sector (and portfolio) news and I will cover them on […]
March 10th Biotech Update
We are up against it. Either these mid-$70s hold on the XBI or we are heading down to around $60. This is not a technical issue at work but two brutal fundamental issues that came to the fore the past couple of days. I will talk through them as opposed to focusing on individual stocks. […]
March 9th Biotech Update
I feel like we are in déjà vu all over again. This year feels like last year where the sector underperforms when the market is weak and underperforms when it is strong. Good news provides only a momentary boost only to be given back and bad news is punished severely. All that being said we […]
March 8th Biotech Update
We remain at a precarious position for the sector and market in general. We had a little bounce, but it was a disappointing ending to what could have been a nice day. Those sorts of reversal do not signal strength. To be fair, there was some more hawkish Fed talk and it is not necessarily […]
March 6th Biotech Update
The week ended on a positive note and it would be good to continue with that move as soon as possible this week. I still sort of worry about the increased rates expectations and how that will ultimately play out in the market/sector. Given the continued strength of the economy I think there is a […]
March 3rd Biotech Update
I am a little torn by the market and sector at this point. Part of me sees the recent weakness and pullback as a natural consolidation and part of me sees it the start of the last major downside related to the rate hike cycle. Expectations of rates have increased and I keep going back […]
March 1st Biotech (and Energy) Update
Well, well, well. A lot happened in the neuro space where there was concerns that it would become significantly more restrictive but I think that is off the table. Is the sector in a better place? I think so as there are a set of broader overhangs that I think it has to work through. […]
